[Indications of G-CSF administration in hematologic disorders]

Area of Science:

• Hematology
• Oncology
• Pharmacology

Context:

• Granulocyte colony-stimulating factors (G-CSF) are crucial in managing myelosuppression from hematologic disorders and chemotherapy.
• G-CSF use is established in lymphoma, offering intensified treatment options and improved outcomes.
• Its role in acute leukemias (ALL, AML), myelodysplastic syndromes (MDS), aplastic anemia (AA), and chronic neutropenia requires further investigation regarding efficacy and long-term effects.

Purpose:

• To review the established and emerging applications of G-CSF in various hematologic conditions.
• To highlight the benefits of G-CSF in reducing neutropenia and enabling dose-intensive therapies.
• To discuss the controversies and areas needing further research, including quality of life, cost-effectiveness, and long-term safety.

Summary:

• G-CSF effectively reduces neutropenia in lymphoma, allowing for more aggressive chemotherapy regimens.
• In acute leukemias, G-CSF's role is debated, while it shows promise in MDS and aplastic anemia with specific considerations.
• G-CSF is a key agent for hematopoietic stem cell mobilization, supporting high-dose therapies.

Impact:

• G-CSF improves treatment tolerance and outcomes in specific hematologic malignancies.
• It facilitates advanced treatment strategies, including high-dose chemotherapy with stem cell support.
• Further research on G-CSF's long-term effects and cost-benefit analysis is essential for optimizing its use.